OPEN ACCESS Freely available online

Mycobacterial Diseases

ISSN: 2161-1068

Short Communication

# Unveiling the Intricacies of *Mycobacteria Tuberculosis* on Human Health

**Roshan Haldi***

*Department of Mycobacterial Diseases, Genskey Medical Technology, Beijing, China*

## DESCRIPTION

Tuberculosis (TB), caused by the *Mycobacterium tuberculosis* complex, remains a significant global health concern. The impact of TB mycobacteria on human health is both profound and intricate, involving a complex interplay between the pathogen and the host immune response. This article explores the characteristics of *tuberculosis mycobacteria*, their interactions with the human body, and the implications for disease progression and treatment.

### Understanding *tuberculosis mycobacteria*

*Mycobacterium tuberculosis*, the bacterium responsible for TB, is a highly evolved and resilient pathogen. It exhibits unique characteristics that contribute to its ability to persist within the human host and evade the immune system. Key features include a thick, lipid-rich cell wall, slow growth rate, and the ability to enter a dormant state, making eradication challenging [1].

### Cell wall composition

The mycobacterial cell wall is distinctive, containing high levels of lipids, including mycolic acids. This lipid-rich structure contributes to the bacterium's resistance to environmental stressors and antimicrobial agents. It also plays a role in the evasion of the host immune response [2].

### Slow growth rate

*Mycobacterium tuberculosis* has a slow growth rate compared to other bacteria. This characteristic influences the dynamics of infection, allowing the bacterium to persist within the host for extended periods, often leading to latent infection [3].

### Dormancy

The ability of TB mycobacteria to enter a dormant state is a critical factor in the establishment of Latent Tuberculosis Infection (LTBI). In this state, the bacteria are metabolically inactive, making them less susceptible to antibiotics and immune surveillance [4].

### Host-pathogen interactions

The interaction between *tuberculosis mycobacteria* and the human host is dynamic and complex. The bacterium employs various strategies to evade the immune system, while the host deploys an array of defense mechanisms to contain and eliminate the infection [5].

### Alveolar macrophages

Upon inhalation, *M. tuberculosis* primarily infects alveolar macrophages in the lungs. These immune cells are tasked with engulfing and digesting pathogens. However, TB mycobacteria can resist digestion and even replicate within macrophages, leading to the establishment of infection [6].

### Granuloma formation

The host's attempt to contain the infection results in the formation of granulomas, organized structures composed of immune cells. While granulomas aim to wall off the bacteria and prevent their spread, they can also serve as a reservoir for persistent infection [7].

### Immune evasion strategies

*M. tuberculosis* employs various strategies to evade immune responses, including inhibiting the maturation of phagosomes within macrophages, modulating host cell death pathways, and altering its surface antigens to evade recognition by the immune system [8].

### Cell-mediated immunity

Cell-mediated immunity plays a crucial role in controlling TB infection. T cells, particularly CD4+ and CD8+ T cells, are essential for recognizing and eliminating infected cells. However, *M. tuberculosis* has evolved mechanisms to subvert T cell responses, contributing to the establishment of latent infection.

### Implications for disease progression

The complex dynamics between *tuberculosis mycobacteria* and the

**Correspondence to:** Roshan Haldi, Department of Mycobacterial Diseases, Genskey Medical Technology, Beijing, China, E-mail: Haldi@roshan.cn

**Received:** 28-Nov-2023, Manuscript No. MDTL-23-28814; **Editor assigned:** 30-Nov-2023, Pre QC No. MDTL-23-28814 (PQ); **Reviewed:** 13-Dec-2023, QC No. MDTL-23-28814; **Revised:** 20-Dec-2023, Manuscript No. MDTL-23-28814 (R); **Published:** 26-Dec-2023, DOI: 10.35248/2161-1068.23.13.417

**Citation:** Haldi R (2023) Unveiling the Intricacies of *Mycobacteria Tuberculosis* on Human Health. Mycobact Dis. 13:417.

host immune response have profound implications for the clinical course of TB. The infection can manifest in various forms, ranging from asymptomatic latent infection to active, symptomatic disease.

### Latent Tuberculosis Infection (LTBI

In LTBI, individuals harbor TB mycobacteria without exhibiting symptoms. The bacteria can remain dormant for years, but the risk of reactivation exists, especially in the presence of immunosuppression or other risk factors.

### Active tuberculosis disease

When the host immune response is compromised or overwhelmed, latent infection can progress to active tuberculosis disease. This may present with pulmonary symptoms, such as cough and hemoptysis, or extrapulmonary manifestations, affecting organs such as the lymph nodes, bones, or central nervous system.

### Drug-resistant TB

The ability of TB mycobacteria to persist and adapt within the host contributes to the emergence of drug-resistant strains. Drug-resistant TB poses a significant challenge to treatment, requiring prolonged and complex therapeutic regimens [9].

### Treatment challenges and strategies

The unique characteristics of *tuberculosis mycobacteria* pose challenges to the development of effective treatment strategies. The slow growth rate, ability to enter dormancy, and resistance to antimicrobial agents complicate the eradication of the infection.

### Standard antibiotic regimens

Standard TB treatment involves a combination of antibiotics, including isoniazid, rifampin, ethambutol, and pyrazinamide. The extended duration of treatment is essential to target both actively dividing and dormant bacteria.

### Drug-resistant TB treatment

Drug-resistant TB requires more prolonged and complex treatment regimens with second-line drugs. The challenges of treatment adherence, potential side effects, and the risk of further resistance underscore the need for innovative therapeutic approaches [10].

### Vaccination strategies

The Bacillus Calmette-Guérin (BCG) vaccine is currently the only licensed TB vaccine, but its efficacy in preventing adult pulmonary TB is variable. Efforts to develop new and more effective vaccines are underway to address the limitations of current vaccination strategies.

## CONCLUSION

*Tuberculosis mycobacteria* exert a profound influence on human health, intricately interacting with the host immune system to establish and persist in various forms of infection. Understanding the characteristics of TB mycobacteria and the complexities of host-pathogen interactions is essential for developing more effective diagnostic tools, treatment strategies, and preventive measures. As global efforts to combat tuberculosis intensify, ongoing research and innovation are crucial to unraveling the mysteries of this ancient yet persistent infectious disease.

## REFERENCES

1. Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: an adaptable pathogen associated with multiple human diseases. Front Cell Infect Microbiol. 2018 May 15;8:158.
2. Allué-Guardia A, García JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12:612675.
3. Chai Q, Wang L, Liu CH, Ge B. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol Immunol. 2020;17(9):901-913.
4. Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. 2017;17(11):691-702.
5. Pérez I, Uranga S, Sayes F, Frigui W, Samper S, Arbués A, et al. Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential. EBioMedicine. 2020;55.
6. Chen JW, Scaria J, Chang YF. Phenotypic and transcriptomic response of auxotrophic Mycobacterium avium subsp. paratuberculosis leuD mutant under environmental stress. PLoS One. 2012;7(6):e37884.
7. Luckner SR, Machutta CA, Tonge PJ, Kisker C. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. Structure. 2009;17(7):1004-1013.
8. Espert L, Beaumelle B, Vergne I. Autophagy in Mycobacterium tuberculosis and HIV infections. Front Cell Infect Microbiol. 2015;5:49.
9. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature. 2013;499(7457):178-183.
10. Bah A, Sanicas M, Nigou J, Guilhot C, Astarie-Dequeker C, Vergne I. The lipid virulence factors of Mycobacterium tuberculosis exert multilayered control over autophagy-related pathways in infected human macrophages. Cells. 2020;9(3):666.